ace

(redirected from angiotensin-converting enzyme inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: item, unit
References in periodicals archive ?
Devaiah, "Angioedema and angiotensin-converting enzyme inhibitors: are demographics a risk?" Otolaryngology--Head and Neck Surgery, vol.
"Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 states." Arch Intern Med.
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.
Start patients on a half tablet daily of the lowest dose available for a fixed-dose combination of a diuretic plus either an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker.
We previously reported that the combined treatment of vitamin K2 (VK) and angiotensin-converting enzyme inhibitor (ACE-I) significantly suppressed the experimental hepatocarcinogenesis.
An angiotensin-converting enzyme inhibitor for reducing the risk of MI, stroke, and death from cardiovascular causes in people aged 55 and over who are at high risk of a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes accompanied by at least one other cardiovascular risk factor.
PHILADELPHIA -- The addition of prednisone to an angiotensin-converting enzyme inhibitor was associated with improved renal survival in a long-term prospective study of patients with proteinuric IgA nephropathy.
The angiotensin-converting enzyme inhibitor (ACEI) ramipril and the angiotensin receptor blocker (ARB) telmisartan are equally effective for secondary cardiovascular prevention.
All were being seen in a heart failure clinic, and 90% were taking an angiotensin-converting enzyme inhibitor, 90% were on a [beta]-blocker, and 93% were on a diuretic.
Angiotensin-converting enzyme inhibitor therapy ought to be extended to a vastly expanded patient population.
To start treatment according to the algorithm, which called for a low dose (half tablet) of a marketed formulation that combined a diuretic with either an angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker, physicians could choose among 11 formulations that were on the Canadian market at the time the study began.

Full browser ?